Literature DB >> 22896003

B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.

Jessica L Allen1, Matthew S Fore, Jenna Wooten, Philip A Roehrs, Nazmim S Bhuiya, Todd Hoffert, Andrew Sharf, Allison M Deal, Paul Armistead, James Coghill, Don A Gabriel, Robert Irons, Amber Essenmacher, Thomas C Shea, Kristy Richards, Corey Cutler, Jerome Ritz, Jonathan Serody, Albert S Baldwin, Stefanie Sarantopoulos.   

Abstract

Recent data reveal an important role for B cells in the pathogenesis of chronic GVHD (cGVHD). Patients with cGVHD have delayed B-cell reconstitution and elevated BAFF to B-cell ratios compared to patients without cGVHD. The mechanisms promoting and sustaining B-cell activation in this disease, however, remain unknown. As BAFF increases murine B-cell metabolism and survival and maintains autoreactive B-cell clones, we performed ex vivo analyses of peripheral B cells from 51 patients who either had or did not have active cGVHD and were greater than 1 year from the time of allogeneic hematopoietic stem cell transplantation. We found that B cells from patients with active cGVHD were in a heightened metabolic state and were resistant to apoptosis. Exogenous BAFF treatment amplified cell size and survival in B cells from these patients. We found significantly increased signaling through ERK and AKT that associated with decreased levels of proapoptotic Bim, suggesting a mechanistic link between elevated BAFF levels and aberrant B-cell survival. Thus, we identify a role for BAFF in the pathogenesis of cGVHD and define B-cell activation and survival pathways suitable for novel therapeutic development in cGVHD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896003      PMCID: PMC3448264          DOI: 10.1182/blood-2012-06-438911

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Rituximab as salvage therapy for refractory chronic GVHD.

Authors:  M Mohty; N Marchetti; J El-Cheikh; C Faucher; S Fürst; D Blaise
Journal:  Bone Marrow Transplant       Date:  2008-02-18       Impact factor: 5.483

2.  Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease.

Authors:  Hildegard T Greinix; David Pohlreich; Michal Kouba; Ulrike Körmöczi; Imke Lohmann; Karin Feldmann; Christoph Zielinski; Winfried F Pickl
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

Review 3.  BH3-only proteins and their roles in programmed cell death.

Authors:  M Giam; D C S Huang; P Bouillet
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

4.  Cutting edge: CD25+ regulatory T cells prevent expansion and induce apoptosis of B cells specific for tissue autoantigens.

Authors:  Isis Ludwig-Portugall; Emma E Hamilton-Williams; Catherine Gottschalk; Christian Kurts
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.

Authors:  Suzanne van Dorp; Floor Pietersma; Matthias Wölfl; Leo F Verdonck; Eefke J Petersen; Henk M Lokhorst; Edwin Martens; Matthias Theobald; Debbie van Baarle; Ellen Meijer; Jürgen Kuball
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-16       Impact factor: 5.742

6.  BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells.

Authors:  Kevin L Otipoby; Yoshiteru Sasaki; Marc Schmidt-Supprian; Alina Patke; Ralph Gareus; Manolis Pasparakis; Alexander Tarakhovsky; Klaus Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-19       Impact factor: 11.205

Review 7.  The role of B cells in the pathogenesis of graft-versus-host disease.

Authors:  Alexander Shimabukuro-Vornhagen; Michael J Hallek; Rainer F Storb; Michael S von Bergwelt-Baildon
Journal:  Blood       Date:  2009-09-11       Impact factor: 22.113

8.  Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL.

Authors:  Micah J Benson; Stacey R Dillon; Emanuela Castigli; Raif S Geha; Shengli Xu; Kong-Peng Lam; Randolph J Noelle
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

9.  Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Corey S Cutler; Nazmim S Bhuiya; Michael Schowalter; Vincent T Ho; Edwin P Alyea; John Koreth; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

Review 10.  Cracking the BAFF code.

Authors:  Fabienne Mackay; Pascal Schneider
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

View more
  61 in total

1.  Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.

Authors:  Zoya Kuzmina; Verena Gounden; Lauren Curtis; Daniele Avila; Tiffani Taylor Rnp; Judy Baruffaldi; Edward W Cowen; Haley B Naik; Sarfaraz A Hasni; Jacqueline W Mays; Sandra Mitchell; Kristin Baird; Seth M Steinberg; Steven Z Pavletic
Journal:  Am J Hematol       Date:  2014-11-24       Impact factor: 10.047

Review 2.  B Cells, Antibodies, and More.

Authors:  William Hoffman; Fadi G Lakkis; Geetha Chalasani
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

3.  IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Authors:  Anushruti Sarvaria; Rafet Basar; Rohtesh S Mehta; Hila Shaim; Muharrem Muftuoglu; Ahmad Khoder; Takuye Sekine; Elif Gokdemir; Kayo Kondo; David Marin; May Daher; Amin M Alousi; Abdullah Alsuliman; Enli Liu; Betul Oran; Amanda Olson; Roy B Jones; Uday Popat; Chitra Hosing; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2016-07-20       Impact factor: 22.113

Review 4.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

5.  An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Authors:  Edouard Forcade; Katelyn Paz; Ryan Flynn; Brad Griesenauer; Tohti Amet; Wei Li; Liangyi Liu; Giorgos Bakoyannis; Di Jiang; Hong Wei Chu; Mercedes Lobera; Jianfei Yang; David S Wilkes; Jing Du; Kate Gartlan; Geoffrey R Hill; Kelli Pa MacDonald; Eduardo L Espada; Patrick Blanco; Jonathan S Serody; John Koreth; Corey S Cutler; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Sophie Paczesny; Bruce R Blazar
Journal:  JCI Insight       Date:  2017-06-15

Review 6.  Aberrant B-cell homeostasis in chronic GVHD.

Authors:  Stefanie Sarantopoulos; Jerome Ritz
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

7.  H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease.

Authors:  Bita Sahaf; Yang Yang; Sally Arai; Leonard A Herzenberg; Leonore A Herzenberg; David B Miklos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 8.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

9.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04

10.  Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Authors:  Caron A Jacobson; Lixian Sun; Haesook T Kim; Sean M McDonough; Carol G Reynolds; Michael Schowalter; John Koreth; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.